Abstract
A midthroughput screening follow-up program targeting the first bromodomain of the human BRD4 protein, BRD4(BD1), identified an acetylated-mimic xanthine derivative inhibitor. This compound binds with an affinity in the low micromolar range yet exerts suitable unexpected selectivity in vitro against the other members of the bromodomain and extra-terminal domain (BET) family. A structure-based program pinpointed a role of the ZA loop, paving the way for the development of potent and selective BET-BRDi probes.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acetylation
-
Cell Cycle Proteins
-
Drug Discovery
-
Humans
-
Models, Molecular
-
Nuclear Proteins / antagonists & inhibitors*
-
Nuclear Proteins / chemistry
-
Nuclear Proteins / metabolism*
-
Protein Structure, Tertiary / drug effects
-
Transcription Factors / antagonists & inhibitors*
-
Transcription Factors / chemistry
-
Transcription Factors / metabolism*
-
Xanthines / chemistry*
-
Xanthines / pharmacology*
Substances
-
BRD4 protein, human
-
Cell Cycle Proteins
-
Nuclear Proteins
-
Transcription Factors
-
Xanthines